Copyright ©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 21, 2022; 28(35): 5129-5140
Published online Sep 21, 2022. doi: 10.3748/wjg.v28.i35.5129
Combination strategies for pharmacologic treatment of non-alcoholic steatohepatitis
Jaspreet Suri, Sebastian Borja, Joseph K Lim
Jaspreet Suri, Department of Gastroenterology, Norwalk Hospital, Norwalk, CT 06856, United States
Sebastian Borja, Department of Internal Medicine, Norwalk Hospital, Norwalk, CT 06850, United States
Joseph K Lim, Section of Digestive Diseases, Yale University School of Medicine, New Haven, CT 06520, United States
Author contributions: Suri J was responsible for background data review, writing, editing and final review of the manuscript; Borja S was responsible for background data review and writing of the manuscript; Lim JK was responsible for writing, editing and final review of the manuscript.
Conflict-of-interest statement: Suri J, None; Borja S, None; Lim JK, research contract (to Yale University) from Allergan, Celgene, Genfit, Intercept, Pfizer, Viking.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:
Corresponding author: Joseph K Lim, MD, Professor, Section of Digestive Diseases, Yale University School of Medicine, Yale Liver Center, 333 Cedar Street, LMP 1080, New Haven, CT 06520, United States.
Received: June 24, 2022
Peer-review started: June 24, 2022
First decision: July 11, 2022
Revised: July 26, 2022
Accepted: August 25, 2022
Article in press: August 25, 2022
Published online: September 21, 2022
Core Tip

Core Tip: Multimodal combination approaches targeting two or more molecular pathways contributing to steatohepatitis and liver fibrosis are needed to augment efficacy of novel investigational drug regimens to achieve non-alcoholic steatohepatitis (NASH) resolution and NASH fibrosis improvement.